## Preterm Birth and Childhood Wheezing Disorders: A Systematic Review and Meta-Analysis

The Harvard community has made this article openly available. **Please share** how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1371/journal.pmed.1001596</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879663">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879663</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Preterm Birth and Childhood Wheezing Disorders: A Systematic Review and Meta-Analysis

Jasper V. Been1,2,3*, Marlies J. Lugtenberg1, Eline Smets1, Constant P. van Schayck2,3, Boris W. Kramer1,4,5, Monique Mommers2, Aziz Sheikh2,3,6

1 Department of Paediatrics, Maastricht University Medical Centre, Maastricht, Netherlands, 2 School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, 3 Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom, 4 School for Oncology and Developmental Biology (GROW), Maastricht University Medical Centre, Maastricht, Netherlands, 5 School of Mental Health and Neuroscience (MHeNS), Maastricht University Medical Centre, Maastricht, Netherlands, 6 Harkness Fellow in Health Care Policy and Practice, Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Background: Accumulating evidence implicates early life factors in the aetiology of non-communicable diseases, including asthma/wheezing disorders. We undertook a systematic review investigating risks of asthma/wheezing disorders in children born preterm, including the increasing numbers who, as a result of advances in neonatal care, now survive very preterm birth.

Methods and Findings: Two reviewers independently searched seven online databases for contemporaneous (1 January 1995–23 September 2013) epidemiological studies investigating the association between preterm birth and asthma/wheezing disorders. Additional studies were identified through reference and citation searches, and contacting international experts. Quality appraisal was undertaken using the Effective Public Health Practice Project instrument. We pooled unadjusted and adjusted effect estimates using random-effects meta-analysis, investigated “dose–response” associations, and undertook subgroup, sensitivity, and meta-regression analyses to assess the robustness of associations. We identified 42 eligible studies from six continents. Twelve were excluded for population overlap, leaving 30 unique studies involving 1,543,639 children. Preterm birth was associated with an increased risk of wheezing disorders in unadjusted (13.7% versus 8.3%; odds ratio [OR] 1.71, 95% CI 1.57–1.87; 26 studies including 1,500,916 children) and adjusted analyses (OR 1.46, 95% CI 1.29–1.65; 17 studies including 874,710 children). The risk was particularly high among children born very preterm (<32 wk gestation; unadjusted: OR 3.00, 95% CI 2.61–3.44; adjusted: OR 2.81, 95% CI 2.55–3.12). Findings were most pronounced for studies with low risk of bias and were consistent across sensitivity analyses. The estimated population-attributable risk of preterm birth for childhood wheezing disorders was ≥3.1%. Key limitations related to the paucity of data from low- and middle-income countries, and risk of residual confounding.

Conclusions: There is compelling evidence that preterm birth—particularly very preterm birth—increases the risk of asthma. Given the projected global increases in children surviving preterm births, research now needs to focus on understanding underlying mechanisms, and then to translate these insights into the development of preventive interventions.

Review Registration: PROSPERO CRD42013004965

Please see later in the article for the Editors’ Summary.
Methods

Search Strategy

This review was performed following the methods detailed in a systematic review protocol registered with PROSPERO (CRD42013004965; Text S1). Online databases were searched independently by two authors using the following search terms: PubMed and Embase: (preterm OR prematurity) AND (asthma OR wheez?); Google Scholar: asthma, wheeze, wheezing, preterm, premature, child, children, childhood; World Health Organization Global Health Library, World Health Organization Library Information System, SciELO, and Trip [12]: (preterm OR premature OR preterms OR prematurity) AND (asthma OR wheeze OR wheezing). The searches covered the period from 1 January 1995 to 23 September 2013. No language restrictions were applied. Additional studies were identified by screening reference lists of articles of interest and tracing citations of articles through ISI Web of Knowledge. We asked an international panel of experts in the field (Text S2) to report any additional published, unpublished, or in progress studies that might have been missed.

Study Selection

Epidemiological studies were eligible for inclusion if they reported an association between preterm birth (<37 wk versus ≥37 wk gestation [term]) and asthma or wheezing in children (aged 0.5 to 18 y). Studies reporting on populations that included children born before 1995 were eligible for inclusion only when at least 50% of the cohort was born from 1995 onwards and none of the children was born before 1990, so as to primarily include studies conducted in the period following the important changes in neonatal practice outlined earlier. When studies with overlapping data were identified, the most informative study was selected for inclusion in this report; the determination of which study was considered most informative was based on consensus, study size being an important determinant. Final study selection was based on a consensus decision between reviewers, with arbitration by a third reviewer in case of disagreement.

Data Extraction

Data were independently extracted from eligible studies by two reviewers (J. V. B. and M. J. L.); disagreements were resolved through discussion, with arbitration by a third reviewer if necessary (A. S.). The following study characteristics were extracted: authors, full reference, study design, location, sample size, inclusion and exclusion criteria, age range and birth year of study participants, method of ascertainment of exposure and outcomes, and outcome measure.

Post-term (>42 wk gestation) births were excluded from the analyses, if possible. If studies reported follow-up at different time points, the most recent was selected. Similarly to previous work [13], we used only one outcome measure from each study in the analyses; for studies with multiple outcome measures, the following hierarchy was used to select the outcome measure used in the analyses, from most preferred to least preferred: asthma, persistent wheezing, recurrent wheezing, severe wheezing, and wheezing. Furthermore, we used the following hierarchy to select the highest ascertainment level if the outcome was measured multiple ways: clinician diagnosis, documented medication use as a wheezing disorder proxy, routinely collected health-care data, parent- or patient-reported clinician diagnosis, parent- or patient-reported medication use, and parent- or patient-reported symptoms. “Ever” wheezing or asthma was favoured over recent and current wheezing or asthma.

Absolute patient counts were extracted to compose 2 x 2 tables according to preterm birth and wheezing disorder status, and these were used to calculate univariate odds ratios (ORs); in instances where relevant crude data were missing, we approached authors to request these. If needed, count data were calculated from provided
percentages, and these were then rounded off to the nearest integer. Adjusted association measures were extracted from the most adjusted model presented.

**Study Quality**

Study quality was assessed independently by two investigators using the Effective Public Health Practice Project quality assessment tool for quantitative studies [14]. Sex, maternal smoking during pregnancy, and maternal atopy or asthma, or a family history of atopy or asthma, were deemed the most important confounders. Any disagreement was resolved by consensus and arbitration by a third reviewer, where necessary.

**Statistical Analyses**

Univariate association measures were pooled using Mantel-Haenszel analysis. Random-effects models were applied because of anticipated heterogeneity given between-country variation in clinical practice and differences in inclusion and exclusion criteria, outcome specification, and ascertainment level of exposure and outcome. Adjusted association measures were pooled via random-effects generic inverse variance analysis. Standard errors for study point estimates were calculated from the respective 95% confidence intervals as described in the Cochrane Handbook [15].

For studies reporting adjusted association measures according to multiple gestational age strata, the least preterm stratum was selected to obtain the most conservative estimate. In a separate analysis, a linear association between gestational age at birth and wheezing disorder risk was investigated, pooling individual studies by random-effects generic inverse variance analysis. For this purpose, adjusted association measures for multiple gestational age strata were aggregated within studies using a fixed-effects log-linear dose–response regression model [16]. The $Q$-statistic and $I^2$-test were used to assess heterogeneity among studies. Small-study effects were assessed using funnel plots and Harbord’s modified regression test for unadjusted data and Egger’s regression test for adjusted association measures.

**Subgroup Analyses**

Subgroup analyses were performed according to age group (<5 y versus ≥5 y) and degree of prematurity (<32 wk versus 32–36 wk). When studies reported the association between preterm birth and wheezing disorders for both subgroups (i.e., follow-up at <5 y and at ≥5 y, and/or reported for <32 wk and 32–36 wk gestation), the corresponding association measures were included in both sides of the comparison.

**Sensitivity Analyses**

Sensitivity analyses were performed according to risk of bias (low, moderate, or high), study size ($n$ ≤10,000 versus $n$ >10,000), and outcome definition (asthma versus wheezing) and ascertainment (clinician diagnosis and/or medication use versus parent-reported outcomes).

**Meta-Regression Analysis**

Meta-regression analysis was performed to assess the independent effects of study size, mean age, wheezing type (wheezing versus asthma), diagnosis ascertainment, and publication year on the association between preterm birth and wheezing disorders.

**Population-Attributable Risk**

PAR was calculated using the following formula:

$$\text{PAR} = \frac{P_e \times (\text{RR}_e - 1)}{1 + P_e \times (\text{RR}_e - 1)}$$

(1)

where $P_e$ is the exposure prevalence and $\text{RR}_e$ is the relative risk due to exposure [17]. $\text{RR}_e$ was calculated as follows:
<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>Birth Year</th>
<th>Country (Region)</th>
<th>Age at Follow-Up</th>
<th>Exposure Ascertainment</th>
<th>Outcome Definition Used in Meta-Analysis</th>
<th>Outcome Ascertainment</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yuan 2003 [51] RC</td>
<td>8,858</td>
<td>Born in North Jutland</td>
<td>None mentioned</td>
<td>1996–1997</td>
<td>Denmark (North Jutland)</td>
<td>1 y</td>
<td>Birth registry (LMP, adjusted by ultrasound if necessary)</td>
<td>Asthma drug prescription (β-agonist and inhaled glucocorticoids)</td>
<td>ATC code R03 in Pharmacoepidemiological Prescription Database of North Jutland</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td>Taveras 2006 PC</td>
<td>763</td>
<td>Singletons born after antenatal care in eight Harvard Vanguard Medical Associates offices</td>
<td>Consent withdrawn, unable to speak English, GA &lt; 34 wk</td>
<td>1999–2002</td>
<td>US (eastern Massachusetts)</td>
<td>2 y</td>
<td>Medical records (LMP/second trimester ultrasound when unreliable)</td>
<td>Asthma in first 2 y</td>
<td>Parent-reported physician diagnosis</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>Gessner 2007 RC</td>
<td>24,979</td>
<td>Children &lt; 10 y enrolled in Medicaid for &gt; 1 y</td>
<td>No match with birth certificate, incomplete data</td>
<td>1994–2001</td>
<td>Taiwan (Kaoshiung)</td>
<td>1–4 y</td>
<td>Birth certificates (LMP)</td>
<td>Asthma</td>
<td>Asthma drug prescription and ICD-9 code 493.xx in Medicaid claims</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Castro-Rodriguez 2010</td>
<td>PC</td>
<td>Spanish children attending primary care centre in area</td>
<td>No contact data, no consent, incomplete data</td>
<td>2006–2007</td>
<td>Spain (Cartagena)</td>
<td>15–18 mo</td>
<td>Wheezing in first year</td>
<td>Parental questionnaire</td>
<td>Moderate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Getahun 2010 RC</td>
<td>397,852</td>
<td>Singletons born alive in KPSC hospitals and enrolled as KPSC health plan members within 60 d of birth</td>
<td>GA &lt; 23 wk, birth defects, neonatal death</td>
<td>1991–2007</td>
<td>US (southern California)</td>
<td>&lt; 8 y</td>
<td>KPSC hospital records (LMP or clinical estimate)</td>
<td>Asthma</td>
<td>ICD-9-Clinical Modification code 493.xx and ≥ 2 asthma drug prescriptions in KPSC hospital records</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Rautava 2010 RC</td>
<td>1,299</td>
<td>Born at &lt; 32 wk or &lt; 1,500 g in level ll–lll hospital in Finland; sex-matched term babies</td>
<td>No personal identifier, 2001–missing/unlikely data, 2002 death &lt; 5 y, address abroad/unknown</td>
<td>Finland</td>
<td>National Medical Birth Register</td>
<td>Asthma</td>
<td>ICD-10 code J45 in National Hospital Discharge Register</td>
<td>High</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Álvaro 2011 RC</td>
<td>119</td>
<td>Born in University Clinical Hospital of Valladolid</td>
<td>No consent</td>
<td>1996–2001</td>
<td>Spain (Valladolid)</td>
<td>5–10 y</td>
<td>Recurrent wheezing at school age</td>
<td>Parental questionnaire</td>
<td>High</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goyal 2011 [33] RC</td>
<td>7,925</td>
<td>Under well-child care of Children’s Hospital of Philadelphia Pediatric Research Consortium from within 30 d of birth to 18 mo</td>
<td>GA &lt; 34 or &gt; 42 wk, major congenital anomalies, hereditary disorders</td>
<td>2007</td>
<td>US (Philadelphia area)</td>
<td>≥ 1.5 y</td>
<td>Birth hospital discharge records (missing data imputed)</td>
<td>Asthma</td>
<td>ICD-9 code 493.xx in practice records</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>Bérand 2012 RC</td>
<td>36,055</td>
<td>Enrolled for at least 3 y in regional insurance (Régie de l’Assurance Maladie du Québec)</td>
<td>None mentioned</td>
<td>1997–2000</td>
<td>Canada (Québec)</td>
<td>3 y</td>
<td>Birth records (MED-ECHO)</td>
<td>Asthma diagnosis in hospital records (MED-ECHO)</td>
<td>ICD-9 code 493</td>
<td>Moderate</td>
<td></td>
</tr>
</tbody>
</table>
## Table 1. Cont.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>Birth Year</th>
<th>Country (Region)</th>
<th>Age at Follow-Up</th>
<th>Exposure Ascertainment</th>
<th>Outcome Definition Used in Meta-Analysis</th>
<th>Outcome Ascertainment</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyle 2012 [22]</td>
<td>RC</td>
<td>14,273 at 3 y; 13,942 at 5 y</td>
<td>Sample of children born in England/Wales Sep 2000-Aug 2001 or in Scotland/ Northern Ireland Nov 2000-Jan 2002 and alive and living in UK at 9 mo</td>
<td>Recent or temporary immigrants, missing or implausible GA</td>
<td>2000–2002</td>
<td>UK</td>
<td>9 mo, 3 y, 5 y</td>
<td>Maternal report of expected due date</td>
<td>Wheezing or whistling in chest in previous year</td>
<td>Parental questionnaire</td>
<td>Moderate</td>
</tr>
<tr>
<td>Robison 2012 [44]</td>
<td>PC</td>
<td>1,448</td>
<td>Singleton children born at Boston Medical Center</td>
<td>No consent, incomplete data</td>
<td>1998–20</td>
<td>US (Boston)</td>
<td>0.5–6 y</td>
<td>Boston Medical Center hospital records (LMP and first trimester ultrasound)</td>
<td>Recurrent (≥4 episodes) wheezing</td>
<td>Physician-documented wheezing in Boston Medical Center medical records</td>
<td>Low</td>
</tr>
<tr>
<td>Sonnen-schein-van der Voort 2012 [54]</td>
<td>PC</td>
<td>5,125</td>
<td>Singleton children born to mothers in selected area of Rotterdam</td>
<td>No consent, no follow-up, born outside follow-up area, subsequent children in same mother, missing birth weight/asthma symptoms</td>
<td>2002–2006</td>
<td>Netherlands (Rotterdam)</td>
<td>1–4 y</td>
<td>Hospital and midwife records</td>
<td>Wheezing</td>
<td>Parental questionnaire</td>
<td>Low</td>
</tr>
<tr>
<td>Collier 2013 [27]</td>
<td>PC</td>
<td>1,428</td>
<td>Singleton from cohort enriched with asthmatic mothers</td>
<td>Non-English-speaking mothers, infant death, no consent, no medical record</td>
<td>1997–2000</td>
<td>US (New England)</td>
<td>6 y (±3 mo)</td>
<td>Unclear</td>
<td>Asthma and wheeze in prior year</td>
<td>Parent-reported physician diagnosis (asthma) or symptom (wheezing)</td>
<td>High</td>
</tr>
<tr>
<td>Escobar 2013 [56]</td>
<td>RC</td>
<td>72,602</td>
<td>In KPNC database and Kaiser Foundation Health Plan membership first 5 y</td>
<td>In-hospital death, GA: &lt;32 wk, incomplete data</td>
<td>1996–2004</td>
<td>US (northern California)</td>
<td>5 y</td>
<td>KPNC database</td>
<td>Asthma? (unadjusted analysis); recurrent wheeze in fifth year after birth (adjusted analysis)</td>
<td>ICD-9 code 493.xx or 786.07, or asthma drug prescription in KPMCP hospital records</td>
<td>Modest</td>
</tr>
<tr>
<td>Vrijlandt 2013 [48]</td>
<td>PC</td>
<td>2,111 at 4 y; 1,523 at 5 y</td>
<td>Preterm babies attending Preventive Child Health Care centre and very preterm babies from neonatal intensive care units; random term controls</td>
<td>Non-response, no consent</td>
<td>2001–2003</td>
<td>Netherlands</td>
<td>4 y, 5 y</td>
<td>Parental questionnaire/medical records</td>
<td>β-agonist ± inhaled glucocorticoid use (4 y; asthma (5 y)</td>
<td>Parental questionnaire</td>
<td>High</td>
</tr>
</tbody>
</table>

*aPlease see Table S2 for detailed assessment.

*b≥3 patient encounters ≥14 d apart, with a diagnosis of asthma or wheezing; and/or ≥1 such encounter with a prescription for oral corticosteroids between 2 d before and 7 d after the encounter; and/or ≥1 hospitalisations for ≥24 h or until death occurred, with a diagnosis of asthma or wheezing; and/or ≥4 dispensing events ≥14 d apart, for which selected asthma medications were prescribed plus ≥1 encounters with a diagnosis of asthma or wheezing; and/or death outside the hospital due to asthma or wheezing.

ATC, Anatomical Therapeutic Chemical Classification System; GA, gestational age; ICD, International Classification of Diseases; KPNC, Kaiser Permanente Northern California; KPSC, Kaiser Permanente Southern California; LMP, last menstrual period; PC, prospective cohort; RC, retrospective cohort.

doi:10.1371/journal.pmed.1001596.s001
### Table 2. Characteristics of included studies: case control and cross-sectional studies.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>Birth Year</th>
<th>Country (Region)</th>
<th>Age at Follow-Up</th>
<th>Exposure Ascertainment</th>
<th>Outcome Definition Used in Meta-Analysis</th>
<th>Outcome Ascertainment</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koshy 2010</td>
<td>CS</td>
<td>933</td>
<td>Children attending primary school in Merseyside</td>
<td>Non-response</td>
<td>1995–2001</td>
<td>UK (Merseyside)</td>
<td>5–11 y</td>
<td>Parental questionnaire</td>
<td>Asthma</td>
<td>Parent-reported physician diagnosis</td>
<td>High</td>
</tr>
<tr>
<td>Visser 2010</td>
<td>CS</td>
<td>1,115</td>
<td>Babies attending 13-mo well baby clinic</td>
<td>No consent</td>
<td>2004–2006</td>
<td>Netherlands (Zwolle area)</td>
<td>13 mo</td>
<td>Unclear</td>
<td>Recurrent (≥4 episodes) wheezing in first year</td>
<td>Parental questionnaire</td>
<td>Moderate</td>
</tr>
<tr>
<td>Civelek 2011</td>
<td>CS</td>
<td>6,219</td>
<td>Random sample of fifth grade students in five cities</td>
<td>None mentioned</td>
<td>1995–1996</td>
<td>Turkey (Ankara, Antalya, Manisa, Trabzon, Van)</td>
<td>10–11 y</td>
<td>Unclear</td>
<td>Recurrent (≥4 episodes) wheezing or whistling in chest in prior year</td>
<td>Parental questionnaire</td>
<td>Moderate</td>
</tr>
<tr>
<td>Fawke 2010</td>
<td>CC</td>
<td>343</td>
<td>GA&lt;25 wk; matched term classmate controls</td>
<td>Lost to follow-up</td>
<td>1995</td>
<td>UK, Ireland</td>
<td>11 y</td>
<td>Hospital records</td>
<td>Asthma medication/ wheeze in prior year and doctor-diagnosed asthma, or asthma medication and wheeze in prior year</td>
<td>Parental questionnaire</td>
<td>High</td>
</tr>
<tr>
<td>Herrera 2011</td>
<td>CS</td>
<td>678</td>
<td>Living in study area for &gt;1 y</td>
<td>Chronic NI/cardiac disease, no consent</td>
<td>2003–2009</td>
<td>Colombia (Bucaramanga)</td>
<td>&lt;7 y</td>
<td>Parental questionnaire</td>
<td>&gt;50% probability of asthma</td>
<td>Parental questionnaire</td>
<td>High</td>
</tr>
<tr>
<td>Brehm 2012</td>
<td>CC</td>
<td>560</td>
<td>Random sample of 6- to 14-y-olds in San Juan</td>
<td>No consent, &gt;1 non-Puerto Rican grandparent</td>
<td>1995–2004</td>
<td>Puerto Rico (San Juan)</td>
<td>6–14 y</td>
<td>Unclear</td>
<td>Asthma and wheeze in the prior year</td>
<td>Parent-reported physician diagnosis (asthma)/ symptom (wheezing)</td>
<td>Moderate</td>
</tr>
<tr>
<td>Cheraghi 2012</td>
<td>CS</td>
<td>3,909</td>
<td>Random sample of school-attending children in Pune</td>
<td>Incomplete data, no consent</td>
<td>1994–1996</td>
<td>India (Pune)</td>
<td>6–7, 13–14 y</td>
<td>Unclear</td>
<td>Ever asthma or wheezing in last year</td>
<td>Parental questionnaire</td>
<td>Moderate</td>
</tr>
<tr>
<td>Fauroux 2013</td>
<td>CC</td>
<td>443</td>
<td>GA&lt;33 wk; matched term newborns born in level 2/3 unit</td>
<td>BPD, respiratory syncytosis pro-phyaxis, non-French-speaking parents, no consent, serious chronic illness</td>
<td>2008–2009</td>
<td>France</td>
<td>1 y</td>
<td>Hospital records</td>
<td>Recurrent (&gt;1 episode) wheezing in first year</td>
<td>Parental questionnaire</td>
<td>High</td>
</tr>
</tbody>
</table>
where PEER is the patient expected event rate. As estimations of PAR based on unadjusted association measures can be biased by confounding of the exposure–outcome relationship, we additionally calculated PAR using aggregated adjusted association measures via the following formula:

$$\text{PAR} = \frac{\text{PD}}{\text{RR}_e}$$

where PD is the proportion of cases exposed [17].

Analyses were performed using Stata 12 (StataCorp).

Role of the Funding Source
The funders had no role in study design, collection, analysis, interpretation of the data, writing of the report, or decision to submit the work for publication.

Results
Forty-two eligible studies were identified [18–59]. Study selection is summarised in Figure 1. Five studies from Sweden [18,20,36,47,55] and two from northern California, US [28,56] had significant population overlap. Furthermore, several eligible studies described the same cohort: the Epicure cohort, UK and Ireland [29,34,41,49]; the Boston Birth Cohort, Boston, US [39,40,44]; a birth cohort from southern New England, US [27,37]; and cross-sectional surveys from Liverpool, UK [38,53]. The most relevant study was selected from each set of overlapping studies. Characteristics of the 12 studies that were excluded, as well as reasons for exclusion, are given in Table S1.

Meta-analysis was performed on the remaining 30 unique studies (Tables 1 and 2), which reported on a total of 1,543,639 individuals [19,21–27,29–33,35,36,42–46,48,50–54,56–59].

Study Quality
Four studies were deemed to have low risk of bias, 12 had high risk of bias (Table S2).

Studied risk of bias in Figure 1. Five studies from Scotland [28,29,31,32,46,48,49,54,56–59]. The most relevant study was selected from each set of overlapping studies. Characteristics of the 12 studies that were excluded, as well as reasons for exclusion, are given in Table S1.

Meta-analysis of Adjusted Data
Seventeen studies provided adjusted association measures that could be pooled in a meta-analysis [35–60]. Although the variables for which individual studies adjusted varied, the variables for which individual studies adjusted varied (Table S3).

Table 2. Cont.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
<th>Birth Year</th>
<th>Country (Region)</th>
<th>Age at Follow-Up</th>
<th>Exposure Ascertained</th>
<th>Outcome Definition Used in Meta-Analysis</th>
<th>Outcome Ascertainment</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshi</td>
<td>CS 2013 [35]</td>
<td>90</td>
<td>GA ≥ 32 wk ± BPD; term controls</td>
<td>Congenital anomalies, cardiopulmonary defect, NDI, non-compliance</td>
<td>1996–2001</td>
<td>UK</td>
<td>8–12 y</td>
<td>Hospital records</td>
<td>Asthma</td>
<td>Parent-reported physician diagnosis</td>
<td>High</td>
</tr>
<tr>
<td>Miyake</td>
<td>CS 2013 [42]</td>
<td>2004</td>
<td>Attending physical examination at seven public health centres</td>
<td>No consent, missing data</td>
<td>2003–2004</td>
<td>Japan (Fukuoka)</td>
<td>3 y</td>
<td>Parental report from Internal and Child Health Handbook</td>
<td>Ever asthma</td>
<td>Parental questionnaire</td>
<td>High</td>
</tr>
<tr>
<td>Nantanda</td>
<td>CS 2013 [59]</td>
<td>614</td>
<td>Presenting at emergency unit with cough and/or dyspnoea and tachypnoea</td>
<td>No consent, cardiac problems</td>
<td>2006–2012</td>
<td>Uganda (Kampala)</td>
<td>0–5 y</td>
<td>Unclear</td>
<td>Asthma&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Post hoc doctor diagnosis based on written records</td>
<td>High</td>
</tr>
</tbody>
</table>

<sup>a</sup> Please see Table S2 for detailed assessment.

<sup>b</sup> High probability of asthma defined as ≥ 4 out of the following five items: (1) ≥ 1 of the following: cough, wheeze, or difficulty breathing; (2) ≥ 1 of the following: recurrent cough, wheeze, and/or difficulty breathing; atopic history in child; history of asthma in first-degree relative; (3) ≥ 3 of the following: fast breathing, chest indrawing, prolonged expiration, or rhonchi; (4) good response to bronchodilators; (5) chest X-ray normal or showing hyperinflation.

CC, case control; CS, cross-sectional; GA, gestational age; NDI, neurodevelopmental impairment.

doi:10.1371/journal.pmed.1001596.t002
the majority included the important confounders: sex, maternal smoking, and parental atopy or asthma. The final summary OR for the association between preterm birth and wheezing disorders was slightly attenuated as compared to the unadjusted analysis (OR 1.46, 95% CI 1.29–1.65, \( p < 0.001 \); Figure 3).

In order to investigate a possible “dose–response” relationship between gestational age at birth and wheezing disorder risk, we aggregated corresponding adjusted association measures from 17 studies (1,105,828 individuals; Figure 4). The pooled estimate of the linear association between gestational age and wheezing disorder

### Table 3. Meta-regression analysis according to study characteristics.

<table>
<thead>
<tr>
<th>Factor</th>
<th>Unadjusted Association Measure</th>
<th>Adjusted Association Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Beta (95% CI)</td>
<td>( p )-Value</td>
</tr>
<tr>
<td>Study size (per 1,000 individuals)</td>
<td>(-0.000 (-0.001 to 0.001))</td>
<td>0.70</td>
</tr>
<tr>
<td>Median population age (years)</td>
<td>0.033 (-0.062 to 0.069)</td>
<td>0.92</td>
</tr>
<tr>
<td>Asthma (reference = wheezing)</td>
<td>0.102 (-0.250 to 0.453)</td>
<td>0.55</td>
</tr>
<tr>
<td>Doctor diagnosis (reference = parental report)</td>
<td>0.009 (-0.333 to 0.352)</td>
<td>0.96</td>
</tr>
<tr>
<td>Year of publication</td>
<td>0.008 (-0.057 to 0.072)</td>
<td>0.80</td>
</tr>
<tr>
<td>Overall</td>
<td>0.99</td>
<td>53%</td>
</tr>
</tbody>
</table>

### doi:10.1377/journal.pmed.1001596.t003

Figure 2. Meta-analysis of unadjusted association between preterm birth and childhood wheezing disorders. Heterogeneity: \( I^2 = 82\% \) (95% CI 75%–87%). PTB, preterm birth; WD, wheezing disorders.

doi:10.1371/journal.pmed.1001596.g002
risk thus obtained (OR 0.94, 95% CI 0.92–0.96, \( p = 0.001 \)) indicated a 6% (95% CI 4%–8%) decrease in wheezing disorder risk for every week increase in gestation length up to 40 wk.

**Subgroup Analyses**

The strength of the association between preterm birth and wheezing disorders was similar between children aged <5 y and older children in both unadjusted and adjusted analyses (Figures S1, S2, S3). The risk was considerably higher among children born very preterm (unadjusted: OR 3.00, 95% CI 2.61–3.44, \( p < 0.001 \); adjusted: OR 2.81, 95% CI 2.52–3.12, \( p < 0.001 \); Figure 5) when compared to moderately preterm children (unadjusted: OR 1.49, 95% CI 1.34–1.66, \( p < 0.001 \); adjusted: OR 1.37, 95% CI 1.17–1.62, \( p < 0.001 \); Figure 6).

**Sensitivity Analyses**

In adjusted analyses, the association between preterm birth and wheezing disorders was most pronounced in the higher quality studies, whereas studies with a high risk of bias had the highest point estimate in the unadjusted analysis (Figures S4, S5, S6). Aggregate ORs did not differ much between subgroups according to study size (Figures S7, S8, S9), diagnosis ascertainment (Figures S10, S11, S12), or wheezing type (Figures S13, S14, S15).

**Meta-Regression Analysis**

To further investigate the independent effects of study size, population age, diagnosis ascertainment, wheezing type, and publication year, meta-regression analysis was performed. None of these factors had an independent effect on the strength of association between preterm birth and wheezing disorders (Table 3). The models’ residual \( I^2 \) values suggested that additional unmeasured factors contributed to between-study heterogeneity.

**Small-Study Effects**

Funnel plot asymmetry was minimal for both unadjusted and adjusted association measures (Figure 7). Accordingly, Harbord’s test (\( p = 0.55 \); unadjusted association measures) and Egger’s test (\( p = 0.43 \); adjusted association measures) revealed no important small-study effects potentially indicative of publication bias.

**Population-Attributable Risk**

Based on unadjusted association measures, the PAR for childhood wheezing disorders associated with preterm birth was estimated at 4.0% overall, comprising 1.6% (95% CI 1.3%–1.9%) for very preterm birth and 2.4% (95% CI 1.7%–3.1%) for moderately preterm birth. PAR based on adjusted association measures was 3.1%: 1.2% (95% CI 1.1%–1.3%) for very preterm
birth and an additional 1.9% (95% CI 1.0%–2.7%) for moderately preterm birth.

**Discussion**

In this meta-analysis of observational studies, using data from over 1.5 million children from across six continents, preterm birth was found to be associated with a 1.71 (95% CI 1.57–1.87) times increased risk of childhood wheezing disorders. The association was slightly attenuated by adjustment for potential confounding within individual studies (OR 1.46, 95% CI 1.29–1.65). Additional analyses strongly support a dose–response relationship between length of gestation and wheezing disorders (OR 0.94, 95% CI 0.92–0.96, per week increase), with children born very preterm having three times the risk of that of children born at term (OR 3.00, 95% CI 2.61–3.44). Consistency across sensitivity analyses further supports the robustness of the findings. Moderate preterm birth accounted for the majority of the explained variation in childhood wheezing disorders by preterm birth. Together, these findings are in line with the increasing recognition of the impact that early life influences have on subsequent health and disease, including pulmonary outcomes [1,8]. Furthermore, they highlight the pressing need for prioritisation of research into prevention of preterm birth and the aetiology of its adverse consequences for subsequent respiratory health.

As with any systematic review we cannot exclude the possibility that potentially relevant studies were missed by our search strategy, although it included the primary online databases for medical research and the most rational search terms relevant to the research question. Identification of additional studies was performed through screening of reference lists and citations, and contacting an international panel of experts. Absence of important small-study effects suggests that bias resulting from selective study inclusion is likely to be minor.

$I^2$ values suggested that considerable heterogeneity was present among the studies included in the meta-analysis, although these values may be inflated by the inclusion of some very large studies [60]. Heterogeneity was handled by applying random-effects models [15]. Low $I^2$ values in subgroup analyses according to age group suggest that between-study population age differences may contribute. Variation furthermore exists among doctors and parents, and between doctors and parents regarding the definition and perception of wheeze, as well as asthma. We therefore performed sensitivity analyses separating wheezing from asthma, and physician diagnoses from parental reports. The results suggest that, although perceptions may differ, this did not affect the

![Figure 4. Meta-analysis of adjusted dose–response association between gestational age (per week increase) and childhood wheezing disorders. Heterogeneity: $I^2 = 90\%$ (95% CI 85%–92%). Individual study adjustment for the primary confounders is depicted. Additional confounders adjusted for are outlined in Table S3. FH, family history; WD, wheezing disorders. doi:10.1371/journal.pmed.1001596.g004](https://www.plosmedicine.org/doi/10.1371/journal.pmed.1001596.g004)
Figure 5. Meta-analysis of association between very preterm birth and childhood wheezing disorders. (A) unadjusted effect estimates; (B) adjusted effect estimates. Subgroups taken from individual studies noted in parentheses. Heterogeneity: $I^2$ (unadjusted) = 62% (95% CI 9%–79%); $I^2$ (adjusted) = 0% (95% CI 0%–68%). Confounders adjusted for in individual studies are outlined in Figure 3 and Table S3. LRI, lower respiratory infection; PTB, preterm birth; WD, wheezing disorders.
doi:10.1371/journal.pmed.1001596.g005
Figure 6. Meta-analysis of association between moderately preterm birth and childhood wheezing disorders. (A) unadjusted effect estimates; (B) adjusted effect estimates. Subgroups taken from individual studies noted in parentheses. Heterogeneity: $I^2$ (unadjusted) = 92% (95% CI 87%–94%); $I^2$ (adjusted) = 89% (95% CI 82%–93%). Confounders adjusted for in individual studies are outlined in Figure 3 and Table S3. LRI, lower respiratory infection; PTB, preterm birth; WD, wheezing disorders.

doi:10.1371/journal.pmed.1001596.g006
estimation of the association between preterm birth and childhood wheezing disorders. Indeed, residual heterogeneity remained after adjustment for these and other factors via meta-regression analysis. Although study quality may be another responsible factor, the observation that aggregated association measures were most pronounced in studies with low risk of bias supports the validity of the conclusions.

Several factors potentially confound the association between preterm birth and wheezing disorders [9]. We therefore performed separate analyses aggregating adjusted association measures. This attenuated the association between preterm birth and wheezing disorders to some degree, as expected. The vast majority of studies adjusted for important potential confounders, although their number and nature varied between studies. A varying degree of residual confounding thus remains, which should be taken into account when interpreting the findings. From studies reporting association measures according to multiple gestational age strata we included the least preterm stratum. The aggregated point estimate is therefore likely to underestimate the actual association.

Different methods for gestational age estimation exist. Although most studies failed to report their approach, first trimester ultrasound is increasingly used in higher income countries. Alternative estimation is usually based on the last menstrual period, which is known to overestimate the numbers of preterm and post-term births [61]. Again, this is expected to result in underestimation of the association between preterm birth and wheezing disorders [62].

In a previous meta-analysis, preterm birth was associated with a 1.37 (95% CI 1.30–1.43) times increased risk of asthma [9]. To better reflect current neonatal practice, we included only cohorts born from the 1990s onwards, resulting in a much larger sample size and negligible overlap with the report by Jaakkola and colleagues [9]. The substantially greater numbers of events in our review enabled us—for the first time—to investigate aggregated adjusted association estimates to account for potential confounding, explore the association with degree of prematurity (i.e., PAR). These additional steps are crucial to interpreting these data, as the evidence is of necessity derived from observational studies, which are inherently at risk of bias. We can only speculate as to the underlying reasons for the association being more pronounced in our report, even after adjustment for confounding. The former review mainly included children born in the 1960s–1980s [9]. These older cohorts are likely to be less preterm on average, which may explain their somewhat lower risk of developing asthma. Analysis by study characteristics in both meta-analyses suggests that the study characteristics are unlikely to explain the difference. The apparent increase over time in wheezing disorder risk associated with preterm birth indicates that changes in neonatal practice have generally failed to improve obstructive pulmonary outcomes in children born preterm.

The current findings do not support prior suggestions that the association between preterm birth and wheezing disorders becomes less prominent with increasing age [9]. Instead, the strength of the association was similar across age groups, suggesting that the pulmonary consequences of preterm birth tend to persist throughout the life course. This observation is supported by evidence from longitudinal studies showing temporal tracking of small airway disease among individuals born preterm [54,56,63], and by recent confirmation of a link between preterm birth and chronic obstructive pulmonary disease [8]. The contribution of atopy to this association is unclear and requires further study.

The processes underlying preterm birth are poorly understood [64]. The incidence as well as the underlying causes of preterm birth are known to vary both geographically and temporally, at least partially driven by meteorological, socioeconomic, ethnic, and (epi)genetic variation [2,64–66]. Environmental exposures, such as pollution and tobacco smoke, and individual behavioural differences (i.e., hygiene, smoking during pregnancy) furthermore contribute [64,65]. Many such factors have also been linked to the development of wheezing disorders [40,44,67]. Through interference with the foetus’s natural environment during critical windows of development, the processes underlying preterm birth challenge the developmental plasticity of the lungs and airways [1,4,43]. Common antecedents of preterm birth such as inflammation, maternal smoking, metabolic derangement, hypoxia, and growth restriction have well-recognised adverse effects on lung maturation and structure, T cell polarisation and development, and airway reactivity [4,31,67–69]. Such alterations can differentially affect susceptibility of the lungs to injurious exposures that commonly follow preterm birth, including sepsis, respiratory infections, mechanical ventilation, and hyperoxia [11,70–72]. For any of

Figure 7. Funnel plots for studies reporting unadjusted and adjusted association measures. (A) unadjusted association measures; (B) adjusted association measures.
doi:10.1371/journal.pmed.1001596.g007
these factors, the likelihood of being exposed increases with decreasing gestational age at birth. Immediate adverse effects are seen in very preterm infants developing BPD, which is an independent risk factor for reactive airway disease [5,29,35,49,67]. Preterm birth furthermore augments the association of several of these risk factors, such as antenatal inflammation and smoke exposure, with childhood wheezing [31,44]. Such mechanisms may all contribute to the observed dose–response relationship between gestational age and adverse respiratory outcomes, including wheezing disorders [4,31]. Genetic influences and gene–environment interactions are furthermore likely to play a role, and the link between preterm birth and asthma has been suggested to at least partially reflect a common genetic background [9,73].

The magnitude of the problem having been established, there is now a pressing need to address several knowledge gaps. Epidemiological studies should concentrate on temporal tracking of respiratory status into adulthood following preterm birth, with particular focus on different wheezing phenotypes, and estimating the relative impact of distinct early life factors on these patterns. Recent accomplishments in combining European birth cohorts can help provide the required numbers [74]. There is, furthermore, a need for additional studies from low- and middle-income countries. More high-quality research is required to identify the underlying mechanisms and accordingly develop appropriate preventive and therapeutic measures. Innovative approaches may combine these aspects, as recently highlighted by a randomised controlled trial of repeated administration of a monoclonal respiratory syncytial virus antibody in moderately preterm infants [75]. The intervention induced an important decrease in wheezing in the first year, establishing the causal link between respiratory syncytial virus and wheezing, as well as offering a possible solution [75]. Immune modulation is beginning to fulfil its promise in neonatal medicine, and preterm babies may well prove particularly favourable targets for the immunomodulatory therapies that are likely to shape the future of asthma management [69,76,77]. The potential for stratified medicine to benefit children born preterm needs to be more generally explored through appropriately designed trials and pre-specified subgroup analyses in future trials.

This work provides compelling evidence that preterm birth is an important early life risk factor for wheezing disorders in childhood. Given the increasing incidence of both entities and their potentially lifelong consequences, there is an urgent need to identify the underlying mechanisms and explore the potential for preventive and therapeutic approaches.

Supporting Information

Checklist S1 PRISMA checklist.

Figure S1 Meta-analysis of unadjusted association between preterm birth and childhood wheezing disorders according to age group. Since estimates from Boyle [22] and Vrijlandt [48] are included on both sides of the comparison, overall association measures are not displayed. Subgroups taken from individual studies noted in parentheses. Heterogeneity: $I^2$ ($\leq 5\, \text{y} = 56\%\ (95\%\ CI\ 0\%–76\%); \quad I^2 \geq 5\, \text{y} = 48\%\ (95\%\ CI\ 0\%–72\%)$). PTB, preterm birth; WD, wheezing disorders.

Figure S2 Meta-analysis of adjusted association between preterm birth and childhood wheezing disorders according to age group. Since estimates from Boyle [22] are included on both sides of the comparison, overall association measures are not displayed. Subgroups taken from individual studies noted in parentheses. Confounders adjusted for in individual studies are outlined in Figure 3 and Table S3. Heterogeneity: $I^2$ ($\leq 5\, \text{y} = 31\%\ (95\%\ CI\ 0\%–77\%); \quad I^2 \geq 5\, \text{y} = 41\%\ (95\%\ CI\ 0\%–69\%)$). PTB, preterm birth; WD, wheezing disorders.

Figure S3 Meta-analysis of adjusted dose–response association between gestational age (per week increase) and childhood wheezing disorders according to age group. Since estimates from Boyle [22] are included on both sides of the comparison, overall association measures are not displayed. Subgroups taken from individual studies noted in parentheses. Heterogeneity: $I^2$ ($\leq 5\, \text{y} = 0\%\ (95\%\ CI\ 0\%–68\%); \quad I^2 \geq 5\, \text{y} = 37\%\ (95\%\ CI\ 0\%–69\%)$). PTB, preterm birth; WD, wheezing disorders.

Figure S4 Meta-analysis of unadjusted association between preterm birth and childhood wheezing disorders according to risk of bias. Heterogeneity: $I^2$ (high risk of bias) $= 60\%\ (95\%\ CI\ 10\%–77\%); \quad I^2$ (moderate risk of bias) $= 63\%\ (95\%\ CI\ 0\%–80\%); \quad I^2$ (low risk of bias) $= 0\%\ (95\%\ CI\ 0\%–68\%)$. PTB, preterm birth; WD, wheezing disorders.

Figure S5 Meta-analysis of adjusted association between preterm birth and childhood wheezing disorders according to risk of bias. Subgroups taken from individual studies noted in parentheses. Confounders adjusted for in individual studies are outlined in Figure 3 and Table S3. Heterogeneity: $I^2$ (high risk of bias) $= 56\%\ (95\%\ CI\ 0\%–92\%); \quad I^2$ (moderate risk of bias) $= 46\%\ (95\%\ CI\ 0\%–73\%); \quad I^2$ (low risk of bias) $= 0\%\ (95\%\ CI\ 0\%–68\%)$. PTB, preterm birth; WD, wheezing disorders.

Figure S6 Meta-analysis of adjusted dose–response association between gestational age (per week increase) and childhood wheezing disorders according to risk of bias. Confounders adjusted for in individual studies are outlined in Figure 4 and Table S3. Heterogeneity: $I^2$ (high risk of bias) $= 39\%\ (95\%\ CI\ 0\%–76\%); \quad I^2$ (moderate risk of bias) $= 63\%\ (95\%\ CI\ 0\%–81\%); \quad I^2$ (low risk of bias) $= 8\%\ (95\%\ CI\ 2\%–90\%)$. WD, wheezing disorders.

Figure S7 Meta-analysis of unadjusted association between preterm birth and childhood wheezing disorders according to study size. Heterogeneity: $I^2$ ($n<10,000) = 47\%\ (95\%\ CI\ 0\%–67\%); \quad I^2 (n\geq 10,000) = 95\%\ (95\%\ CI\ 93\%–97\%)$. PTB, preterm birth; WD, wheezing disorders.

Figure S8 Meta-analysis of adjusted association between preterm birth and childhood wheezing disorders according to study size. Subgroups taken from individual studies noted in parentheses. Confounders adjusted for in individual studies are outlined in Figure 3 and Table S3. Heterogeneity: $I^2$ ($n<10,000) = 42\%\ (95\%\ CI\ 0\%–68\%); \quad I^2 (n\geq 10,000) = 94\%\ (95\%\ CI\ 89\%–96\%)$. PTB, preterm birth; WD, wheezing disorders.

Figure S9 Meta-analysis of adjusted dose–response association between gestational age (per week increase) and childhood wheezing disorders according to study size.
size. Confounders adjusted for in individual studies are outlined in Figure 4 and Table S3. Heterogeneity: $\hat{R}$ (parent reported) $= 43\%$ (95\% CI 0\%–71\%); $\hat{R}$ (doctor diagnosed) $= 90\%$ (95\% CI 82\%–93\%). PTB, preterm birth; WD, wheezing disorders.

Figure S10 Meta-analysis of unadjusted association between preterm birth and childhood wheezing disord- ers according to diagnosis ascertainment. Heterogeneity: $\hat{R}$ (parent reported) $= 19\%$ (95\% CI 0\%–55\%); $\hat{R}$ (doctor diagnosed) $= 93\%$ (95\% CI 89\%–95\%). PTB, preterm birth; WD, wheezing disorders.

Figure S11 Meta-analysis of adjusted association between preterm birth and childhood wheezing disorders according to diagnosis ascertainment. Subgroups taken from individual studies noted in parentheses. Confounders adjusted for in individual studies are outlined in Figure 3 and Table S3. Heterogeneity: $\hat{R}$ (parent reported) $= 54\%$ (95\% CI 0\%–76\%); $\hat{R}$ (doctor diagnosed) $= 95\%$ (95\% CI 92\%–96\%). WD, wheezing disorders.

Figure S12 Meta-analysis of adjusted dose–response association between gestational age (per week increase) and childhood wheezing disorders according to diagnosis ascertainment. Confounders adjusted for in individual studies are outlined in Figure 4 and Table S3. Heterogeneity: $\hat{R}$ (wheezing) $= 52\%$ (95\% CI 0\%–76\%); $\hat{R}$ (asthma) $= 86\%$ (95\% CI 79\%–90\%). PTB, preterm birth; WD, wheezing disorders.

Figure S13 Meta-analysis of unadjusted association between preterm birth and wheezing disorders according to wheezing type. Heterogeneity: $\hat{R}$ (wheezing) $= 41\%$ (95\% CI 0\%–74\%); $\hat{R}$ (asthma) $= 86\%$ (95\% CI 76\%–90\%). PTB, preterm birth; WD, wheezing disorders.

Figure S14 Meta-analysis of adjusted association between preterm birth and childhood wheezing disorders according to wheezing type. Subgroups taken from individual studies noted in parentheses. Confounders adjusted for in individual studies are outlined in Figure 3 and Table S3. Heterogeneity: $\hat{R}$ (wheezing) $= 41\%$ (95\% CI 0\%–74\%); $\hat{R}$ (asthma) $= 86\%$ (95\% CI 76\%–90\%). PTB, preterm birth; WD, wheezing disorders.

Figure S15 Meta-analysis of adjusted dose–response association between gestational age (per week increase) and childhood wheezing disorders according to wheezing type. Confounders adjusted for in individual studies are outlined in Figure 4 and Table S3. Heterogeneity: $\hat{R}$ (wheezing) $= 52\%$ (95\% CI 0\%–78\%); $\hat{R}$ (asthma) $= 92\%$ (95\% CI 87\%–94\%). WD, wheezing disorders.

Table S1 Characteristics of studies excluded because of population overlap. *Selected inhaled or systemic adrenergics, anticholinergics, xantines, antiallergics, leukotriene receptor antagonists, and/or steroids; ** as compared to preterm babies without BPD. GA, gestational age; KFHP, Kaiser Foundation Health Plan; KPMCP, Kaiser Permanente Medical Care Program; N/R, not reported; LMP, last menstrual period; SD, standard deviation.

Table S2 Assessment of study quality. Scoring according to the Effective Public Health Practice Project quality assessment tool for quantitative studies. For study design “?” indicates cross-sectional design in all cases. N/A, not applicable.

Table S3 Covariates in multivariate models of individual studies associating preterm birth with wheezing disorders. *month of conception, maternal urinary tract infection, pre-labour rupture of membranes, prostaglandin induction, neonatal jaundice, neonatal sepsis; †threatened miscarriage, infections, asthysia, birth trauma, premature rupture of membranes, umbilical cord knots, placenta problems; ‡CC10 G+3/A polymorphisms, cord blood IgE.

Text S1 PROSPERO-registered review protocol.

Text S2 Expert panel.

Acknowledgments

We thank Professor Paul Brand, Dr. Liesbeth Duijts, Dr. Gabriel Escobar, Dr. Neera Goyal, Dr. Gibby Koshy, Professor Bulent Sekerel, and Dr. Agnes Sonnenschein-van der Voort for kindly providing additional data and information to facilitate data analysis. Furthermore, we thank Dr. Liesbeth Duijts, Professor Bengt Källén, Professor Scott Weiss, and other members of the expert panel for providing advice. We thank Dr. Niall Anderson and Dr. Ulugbek Nurmatov for statistical advice.

Author Contributions

Conceived and designed the experiments: JVB BWK MM AS. Performed the experiments: JVB MJL ES. Analyzed the data: JVB MJL. Wrote the first draft of the manuscript: JVB MJL AS. Contributed to the writing of the manuscript: JVB MJL ES BWK CP/S MM AS. ICMJE criteria for authorship read and met: JVB MJL ES CPvS BWK MM AS. Agree with the manuscript results and conclusions: JVB MJL ES BWK CP/S MM AS. Secured funding: JVB CP/S. Systematic literature review: JVB MJL ES. Quality assessment: JVB MJL ES. Data-extraction: JVB MJL.

References

Editors’ Summary

Background. Most pregnancies last around 40 weeks, but worldwide, more than 11% of babies are born before 37 weeks of gestation (the period during which a baby develops in its mother’s womb). Preterm birth is a major cause of infant death—more than 1 million babies die annually from preterm birth complications—and the number of preterm births is increasing globally. Multiple pregnancies, infections, and chronic (long-term) maternal conditions such as diabetes can all cause premature birth, but the cause of many preterm births is unknown. The most obvious immediate complication that is associated with preterm birth is respiratory distress syndrome. This breathing problem, which is more common in early preterm babies than in near-term babies, occurs because the lungs of premature babies are structurally immature and lack pulmonary surfactant, a unique mixture of lipids and proteins that coats the inner lining of the lungs and helps to prevent the collapse of the small air sacs in the lungs that absorb oxygen from the air. Consequently, preterm babies often need help with their breathing and oxygen supplementation.

Why Was This Study Done? Improvements in the management of prematurity mean that more preterm babies survive today than in the past. However, accumulating evidence suggests that early life events are involved in the subsequent development of non-communicable diseases (non-infectious chronic diseases). Given the increasing burden of preterm birth, a better understanding of the long-term effects of preterm birth is essential. Here, the researchers investigate the risks of asthma and wheezing disorders in children who are born preterm by undertaking a systematic review (a study that uses predefined criteria to identify all the research on a given topic) and a meta-analysis (a statistical method for combining the results of several studies). Asthma is a chronic condition that is caused by inflammation of the airways. In people with asthma, the airways can react very strongly to allergens such as animal fur and to irritants such as cigarette smoke. Exercise, cold air, and infections can also trigger asthma attacks, which can sometimes be fatal. The symptoms of asthma include wheezing (a high-pitched whistling sound during breathing), coughing, chest tightness, and shortness of breath. Asthma cannot be cured, but drugs can relieve its symptoms and prevent acute asthma attacks.

What Did the Researchers Do and Find? The researchers identified 30 studies undertaken between 1995 and the present (a time span chosen to allow for recent changes in the management of prematurity) that investigated the association between preterm birth and asthma/wheezing disorders in more than 1.5 million children. Across the studies, 13.7% of preterm babies developed asthma/wheezing disorders during childhood, compared to only 8.3% of babies born at term. Thus, the risk of preterm babies developing asthma or a wheezing disorder during childhood was 1.71 times higher than the risk of term babies developing these conditions (an unadjusted odds ratio [OR] of 1.71). In analyses that allowed for confounding factors—other factors that affect the risk of developing asthma/wheezing disorders such as maternal smoking—the risk of preterm babies developing asthma or a wheezing disorder during childhood was 1.46 times higher than that of babies born at term (an adjusted OR of 1.46). Notably, compared to children born at term, children born very early (before 32 weeks of gestation) had about three times the risk of developing asthma/wheezing disorders in unadjusted and adjusted analyses. Finally, the population-attributable risk of preterm birth for childhood wheezing disorders was more than 3.1%. That is, if no preterm births had occurred, there would have been more than a 3.1% reduction in childhood wheezing disorders.

What Do These Findings Mean? These findings strongly suggest that preterm birth increases the risk of asthma and wheezing disorders during childhood and that the risk of asthma/wheezing disorders increases as the degree of prematurity increases. The accuracy of these findings may be affected, however, by residual confounding. That is, preterm children may share other, unknown characteristics that increase their risk of developing asthma/wheezing disorders. Moreover, the generalizability of these findings is limited by the lack of data from low- and middle-income countries. However, given the projected global increases in children surviving preterm births, these findings highlight the need to undertake research into the mechanisms underlying the association between preterm birth and asthma/wheezing disorders and the need to develop appropriate preventative and therapeutic measures.

Additional Information. Please access these websites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1001596.

- The March of Dimes, a nonprofit organization for pregnancy and baby health, provides information on preterm birth (in English and Spanish)
- Nemours, another nonprofit organization for child health, also provides information (in English and Spanish) on premature babies and on asthma (including personal stories)
- The UK National Health Service Choices website provides information about premature labor and birth and a real story about having a preterm baby; it provides information about asthma in children (including real stories)
- The MedlinePlus Encyclopedia has pages on preterm birth, asthma, asthma in children, and wheezing (in English and Spanish); MedlinePlus provides links to further information on premature birth, asthma, and asthma in children (in English and Spanish)